Filtered By:
Condition: Bleeding
Countries: China Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 253 results found since Jan 2013.
GDF ‐15 at admission predicts cardiovascular death, heart failure, and bleeding outcomes in patients with CAD
ConclusionsIn patients with CAD, admission levels of GDF-15 were associated with an increased 1 year risk of CV death, HF, and bleeding outcomes, but not with thrombotic events. GDF-15 may be a prognostic biomarker for CV death, HF, and bleeding outcomes and could be used to refine the risk assessment of these specific clinical outcomes.Trial Registration:ClinicalTrials.gov Identifier: NCT04044066
Source: ESC Heart Failure - August 25, 2023 Category: Cardiology Authors: Jiali Wang,
Tao Zhang,
Feng Xu,
Wei Gao,
Ming Chen,
Huadong Zhu,
Jun Xu,
Xinxin Yin,
Jiaojiao Pang,
Song Zhang,
Mengke Wei,
Jiahao Chen,
Ying Liu,
Xuezhong Yu,
Derek P. Chew,
Yuguo Chen Tags: Original Article Source Type: research
The contribution of genotype-guided selection of P2Y12 inhibitor on prognosis in ACS /CCS patients undergoing percutaneous coronary intervention: a retrospective cohort study
ConclusionsGenotype-guided selection of P2Y12 inhibitor made a very positive contribution on the prognosis in Chinese ACS/CCS patients undergoing PCI. Instead of intensifying antiplatelet strategies, conventional-dose clopidogrel could be recommended as P2Y12 inhibitor after weighing MACEs and bleeding events in CYP2C19 IM patients.
Source: European Journal of Clinical Pharmacology - July 14, 2023 Category: Drugs & Pharmacology Source Type: research
Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack
CMAJ. 2023 Jul 10;195(26):E897-E904. doi: 10.1503/cmaj.230262.ABSTRACTBACKGROUND: Body mass index (BMI) may affect the response to platelet P2Y12 receptor inhibitors. We aimed to explore whether BMI influenced the efficacy and safety of ticagrelor and clopidogrel for secondary prevention of minor ischemic stroke or transient ischemic attack (TIA) among patients enrolled in the CHANCE-2 (Ticagrelor or Clopidogrel with Aspirin in High-Risk Patients with Acute Nondisabling Cerebrovascular Events II) trial.METHODS: In a multicentre, randomized, double-blind, placebo-controlled trial, conducted in China, we randomized patients ...
Source: Canadian Medical Association Journal - July 10, 2023 Category: General Medicine Authors: Jia Zhang Anxin Wang Xue Tian Xia Meng Xuewei Xie Jing Jing Jinxi Lin Yilong Wang Zixiao Li Liping Liu Hao Li Yong Jiang Xingquan Zhao Yongjun Wang Source Type: research
Correction: Stroke prevention of thoracoscopic left atrial appendage clipping in patients with non-valvular atrial fibrillation at high risk of stroke and bleeding: study protocol for a non-randomised controlled clinical trial
This article has been corrected since it was published online. The affiliation numbers 1 and 2 have been merged and updated to "Department of Cardiac Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China".
Source: BMJ Open - June 1, 2023 Category: General Medicine Tags: Open access Correction Source Type: research
Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (STRATEGY): protocol for a multicentre, randomised controlled trial
DISCUSSION: The STRATEGY trial will assess whether tirofiban combined with aspirin is effective and safe in preventing recurrence and END in patients with PAI.TRIAL REGISTRATION NUMBER: NCT05310968.PMID:37220998 | DOI:10.1136/svn-2022-002284
Source: Atherosclerosis - May 23, 2023 Category: Cardiology Authors: Xiaoling Liao Shuo Feng Yicong Wang Yuesong Pan Weiqi Chen Hui Qu Xingquan Zhao Liping Liu Yongjun Wang Yilong Wang Source Type: research
Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials
Conclusion: Ticagrelor increased the risk of bleeding and did not increase treatment efficacy compared to that of clopidogrel in the East Asian population who have ACS treated with PCI.
Source: Cardiology - April 24, 2023 Category: Cardiology Source Type: research
